Sorrento Therapeutics (NASDAQ: SRNE)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-04 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-30 | ||||||
REV |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Sorrento Therapeutics (NASDAQ: SRNE) through any online brokerage.
Other companies in Sorrento Therapeutics’s space includes: Avidity Biosciences (NASDAQ:RNA), Valneva (NASDAQ:VALN), Cogent Biosciences (NASDAQ:COGT), Replimune Group (NASDAQ:REPL) and CareDx (NASDAQ:CDNA).
The latest price target for Sorrento Therapeutics (NASDAQ: SRNE) was reported by HC Wainwright & Co. on Friday, March 25, 2022. The analyst firm set a price target for 20.00 expecting SRNE to rise to within 12 months (a possible 843.40% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Sorrento Therapeutics (NASDAQ: SRNE) is $2.12 last updated Today at August 17, 2022, 8:00 PM UTC.
There are no upcoming dividends for Sorrento Therapeutics.
Sorrento Therapeutics’s Q3 earnings are confirmed for Friday, November 4, 2022.
There is no upcoming split for Sorrento Therapeutics.
Sorrento Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.